No spam - just the good stuff

Subscribe to our newsletter

News

Nanotech

Nanoparticles to strip away senescent cell defences

Nano drug-delivery system developed for neurological disorders

Longevity Escape Velocity within 10 years?

Bestselling book enters new markets and predicts Longevity Escape Velocity by 2029/30.

Clene goes for gold, and goes public

Longevity companies to watch in 2021

A year in Longevity: different perspectives

Neurotech2020 – a clear head for neurotech, research and investment

Longevity boost as nanotech reveals inner cell workings

The natural medicine war chest to fight aging

Astellas to acquire iota Biosciences

Neurotech2020: It’s a brave new world

Deliver us from aging – the Quicksilver method

The X-factor required for bio-printed growth success

Cutting surgical robots down to size

Nanotech ‘passport to the brain’ for therapeutics

Nanoparticles target immune response using red blood cells

When scaling down is as vital as scaling up

NaNotics raising Series B to support Asia-Pacific trials

Novel approach breaks through blood-brain barrier

Building an artificial immune system

Longevity and the Singularity

Making the Longevity grade: expanded list of 1000 leading names

Longevity and the art of motorcycle maintenance

Longevity2020: Day 3 recap

Longevity 2020: shaping-up nicely

Biological and artificial neurons linked using standard IP

Some good news: announcing Longevity2020

Longevity is bigger on the inside: CNS regeneration

J&J enters Longevity market with “Immorbidity” play

Plaque eating nanoparticle prevents heart attacks

Precious nano metals hold key to new treatments

Super-human blood for targeted delivery

Find us here ...

Subscribe to our newsletter

© Copyright 2023 FIRST LONGEVITY Limited. All rights reserved. FIRST LONGEVITY

The information included in this website is for informational purposes only: its purpose is to promote a broad consumer understanding a knowledge of various health topics. It is not intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.

DISCLAIMER FOR U.S. BASED INVESTORS

The Agent of First Longevity Limited in the United States is Marco Polo Securities Inc, a non-affiliated broker-dealer registered with the US Securities and Exchange Commission. The activities of First Longevity Limited in the United States will be affected only to the extent permitted by Rule 15a-6 under the US Securities Exchange Act of 1934 and in accordance with the Services Agreement entered into between First Longevity Limited and Marco Polo Securities Inc with respect thereto. Contact at Marco Polo Securities is clientservices@mpsecurities.com; 1-347-745-6448.